Full Press Release Details
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development.
LXRX
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Key Takeaway: Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
Price reaction · baseline $2.32 (2023-06-22 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close
+2.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus